Browsing Tag
Dravet Syndrome
6 posts
Stoke Therapeutics has enrolled its pivotal Dravet trial, but what must the August 3 call prove?
Stoke Therapeutics will discuss its second-quarter performance on August 3 after completing enrollment in the pivotal EMPEROR trial. Investors will be looking beyond quarterly revenue to assess spending, regulatory execution and preparations for a possible zorevunersen launch.
Two years in, is Lundbeck’s bexicaserin redefining how we treat drug-resistant seizures?
Lundbeck’s bexicaserin shows two-year seizure control in rare epilepsies. Explore how the durable data could redefine drug development in childhood DEEs.
Longboard Pharmaceuticals shares see spike as FDA recognizes potential of bexicaserin in Dravet syndrome
Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted…
Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to…
Zogenix bags Fintepla FDA approval for Dravet syndrome treatment
Fintepla FDA approval : Zogenix has bagged approval from the US Food and Drug Administration (FDA) for Fintepla…
Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome
US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from…